Man Group
PGNX

Man Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Man Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-19,000
Closed -$88K – 2084
2019
Q1 		$88K Buy
+19,000
New +$86K ﹤0.01% 1917
2018
Q4 		– Sell
-30,937
Closed -$194K – 2217
2018
Q3 		$194K Buy
30,937
+19,173
+163% +$147K ﹤0.01% 2024
2018
Q2 		$95K Buy
+11,764
New +$89.8K ﹤0.01% 2073

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Man Group's PGNX Position: Q2 2019 in Review

Man Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 19,000 shares — an estimated $88K sold.

Man Group first reported a position in PGNX in Q2 2018 and held it in 3 quarters. The position peaked at $194K in Q3 2018. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

  • Man Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
  • Man Group sold 19,000 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $88K.
  • Man Group first reported a position in Progenics Pharmaceuticals Inc in Q2 2018 and held it in 3 quarters.
  • Man Group's Progenics Pharmaceuticals Inc position peaked at $194K in Q3 2018.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Man Group's 13F filing for Q2 2019, filed 14 Aug 2019.